Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 8 at 2:00 PM EDT

Register Free →
logo
Get CLEATUSFree Trial

Engineering Biological and Biomedical Systems (EBBS)

Active
PD-26-369YGrant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Engineering Biological and Biomedical Systems (EBBS) program, offered by the U.S. National Science Foundation, focuses on advancing the understanding and engineering of biological and physiological systems to improve human health and maintain U.S. leadership in biotechnology. This program supports research that combines fundamental mechanistic insights with experimental and computational methods to develop innovative platforms, devices, tissues, and organisms. Emphasis is placed on studies exploring microbial and therapeutic cell behaviors, novel biosensing and imaging technologies, and the design of biological systems capable of sensing and responding to new stimuli. Projects contributing to tissue restoration, injury insights, and rehabilitation engineering, particularly those addressing the needs of persons with disabilities, are also supported. The EBBS program encourages research that expands biomanufacturing and leads to improved biological processes, novel biomedical technologies, or new understandings of physiological and pathological mechanisms. However, it explicitly excludes proposals primarily focused on drug design, drug delivery, disease model development, therapy testing, validation, and clinical trials. Limited human volunteer studies may be supported if they align with project objectives. Projects aiming at commercialization are better suited for the NSF Directorate for Technology, Innovation, and Partnerships. To foster innovation, the NSF collaborates with federal agencies, industry, and international partners, offering further opportunities through NSF ENG Partnerships. The solicitation for this program was posted on April 24, 2026, with the U.S. National Science Foundation as the administering agency.

General Info

NSF EBBS funds research advancing engineered biological systems, excluding drug-focused studies.

Agency

U.S. National Science FoundationView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseSolicitation
Posted

Solicitation

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyU.S. National Science Foundation
Contacts1 person available
OfficeUS
Organization / Agency
U.S. National Science Foundation
View Agency Profile
Office AddressUS
Contacts
U.S. National Science Foundation
contact@example.gov
+1 (555) 000-0000

Full Description

Show more
The Engineering Biological and Biomedical Systems (EBBS) program expands our understanding of biological and physiological systems, and it helps improve human health. For U.S. leadership in biotechnology, the engineering of biology is required at every scale. Engineering is needed for sensing biomarkers to making proteins to restoring functions of the body. In EBBS, fundamental mechanistic insights are combined with experimental and computational techniques. This approach helps develop platforms, devices, organisms, tissues, and processes that bring new understanding and control of biological functions.
EBBS supports studies of mechanisms that drive the behavior of microbial populations and cells, and of therapeutic cells and tissues. This includes discovering the underlying engineering principles that are needed to capture the responses of biological systems and bioreactors. It also includes the creation of novel biosensing platforms and new optical imaging and modulation strategies. Research that enables the design of biological systems to sense and respond to novel stimuli is welcome. Similarly, projects leading to insight into tissue changes or injury, and to systems that imitate or restore the functions of tissues or organs are encouraged.
Projects that advance rehabilitation engineering through new theories and approaches are supported by the EBBS program. Fundamental engineering research driven by the needs of persons with disabilities is encouraged.
The EBBS program expands what is possible in biomanufacturing; research may advance biotechnology and/or health. EBBS research must enable improved biological processes, create novel biomedical technologies, or achieve new understanding of physiological or pathological processes.
EBBS does not support proposals with a main goal of drug design, drug delivery, or the development of animal models of disease. Using existing models for experimental testing and validation is acceptable. Projects that focus on testing and validating therapies are not supported. Clinical trials are not supported. Limited studies involving human volunteers may be supported if appropriate to the project objectives. Projects focused on commercialization are more appropriate for the NSF Directorate for Technology, Innovation, and Partnerships (TIP).
Partnerships: To speed discovery and innovation, NSF partners with federal agencies, industry, international groups, and others. Current opportunities are at NSF ENG Partnerships.

Similar Contracts

NAICS: 541714
New
Federal
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3The RAPIID program, specifically Task Area 3, aims to bridge the gap between lab-scale breakthroughs in shelf-stable blood analogs and real-world deployment by advancing the regulatory approval, manufacturing scalability, and field usability of components originally developed under the FSHARP program. These components, designed to replicate the critical functions of whole blood—oxygen delivery, hemostasis, and volume expansion—now require rigorous clinical validation to demonstrate safety and efficacy when used in combination, as well as scalable production processes to ensure consistent, high-volume output. Efforts under this solicitation will focus on pushing these technologies through the regulatory pathway to secure necessary approvals for military and civilian use in austere, pre-hospital environments. The initiative seeks to develop and scale enabling fielding technologies that support the deployment, storage, and administration of these blood analogs outside controlled laboratory settings. This includes not only the components themselves but also the logistical and operational frameworks needed to integrate them into frontline medical workflows. Proposals must address the full spectrum of challenges—from manufacturing robustness and regulatory compliance to usability in extreme conditions—while aligning with the program’s goal of delivering a complete, authorized system capable of saving lives where traditional blood supplies are unavailable. The solicitation, issued by DARPA’s Biological Technologies Office, has a response deadline of July 29, 2026, and is open to all qualified entities, targeting the NAICS code 541714 for research and development in physical, engineering, and life sciences.
Defense Advanced Research Projects Agcy

POSTED

3 days ago

DEADLINE

in 25 days
View Details
NAICS: 541714
New
Federal
Chromosome Conformation and Whole Genome Sequencing - KINGSTON RIThis contract solicitation seeks quotations for chromosome conformation and whole genome sequencing services under solicitation number 1232SA26Q0618, issued as a combined synopsis and request for quotation in accordance with FAR Part 12. The acquisition is exclusively reserved for small business concerns, with a total small business set-aside designation, and is restricted to entities that do not exceed 1,000 employees as defined by the North American Industry Classification System code 541714. All responsible small businesses are eligible to submit a quote, and no separate written solicitation will be issued—this announcement serves as the complete and only solicitation document. The work is to be performed in Kingston, Rhode Island, with the contracting office located in Beltsville, Maryland, under the auspices of the USDA Agricultural Research Service. The solicitation was posted on July 2, 2026, and responses are due by July 10, 2026, at 10:00 PM Eastern Time. All inquiries should be directed to Shane Pope, the primary point of contact, via email at shane.pope@usda.gov or by phone at 970-851-3735. The opportunity is accessible through the SAM.gov platform, and bidders must ensure full compliance with federal commercial item procurement guidelines.
USDA Ars Afm Apd

POSTED

3 days ago

DEADLINE

in 6 days
View Details
NAICS: 541714
New
Federal
RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)The Biomedical Advanced Research and Development Authority (BARDA), under the U.S. Department of Health and Human Services, is seeking proposals through Request for Proposal 75A50126R00002 to advance the late-stage clinical development and regulatory approval of 2-PAM autoinjectors as a drug/device combination product for the treatment of organophosphate poisoning, including nerve agents, in both adult and pediatric populations. The contract also encompasses the procurement of these autoinjectors for inclusion in the Strategic National Stockpile (SNS) and CHEMPACK programs. The solicitation requires offerors to demonstrate the capability to manufacture 600 mg 2-PAM autoinjectors at a Phase 3 clinical level or higher, with full FDA approval readiness. Proposals must include a comprehensive technical approach covering risk mitigation, project management, inventory control, and post-market surveillance, with mandatory compliance with current Good Manufacturing Practices and FDA guidance for emergency use or approved medical products. The contract features a base period of up to 36 months with up to three optional periods extending performance to a total of 10 years, involving a total potential procurement of 2 million adult-dose autoinjectors across four separate firm-fixed-price line items, each for 500,000 units, supported by cost-plus-fixed-fee line items for development and post-market activities. Deliveries are FOB destination to BARDA’s facility in Washington, D.C., with the contractor responsible for product integrity, temperature control (8–25°C), and security—including GPS tracking, tamper-resistant sealing, and TempTale documentation—until formal government acceptance. Evaluation is conducted on a best-value trade-off basis, with mandatory technical and infrastructure criteria serving as disqualifying thresholds, followed by technical approach, past performance, and cost. Offerors must be current in SAM with a valid UEI and CAGE code, and are subject to strict organizational conflict of interest disclosures, key personnel notification requirements, and prohibitions on the use of funds for abortions, needle distribution for illegal drug use, or human embryo research. Proposals must be submitted electronically via the BDR Portal by July 30, 2026, structured in three distinct volumes under strict page limits, with compliance to HHSAR and FAR clauses governing supply chain risk, anti-lobbying, and inspection standards.
Barda - Aspr / Daappo / Barda Dcma

POSTED

3 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
Grant
NIDDK Disease Research and Translational Core Centers (P30 Clinical Trial Optional)The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is inviting applications for Disease Research and Translational Core Centers under the P30 mechanism, which is clinical trial optional. These centers aim to strengthen existing research institutions with established programs in cystic fibrosis, diabetes, nutrition, obesity, liver, and digestive diseases by fostering multidisciplinary collaboration, improving research rigor and reproducibility, and enhancing cost efficiency. The centers are structured around shared core services that provide access to specialized equipment, technical resources, analytical support, and expert-led training, all tailored to the specific needs of the research community within the institution. They also include a Pilot and Feasibility Grant Program to support new projects and a Scientific Catalyst Program administered through the Administrative Core, which promotes team building, mentoring, workshops, seminars, and visits by expert scientists to stimulate innovation and attract new investigators to the field. The program places strong emphasis on creating a nurturing environment for trainees and early-stage investigators, ensuring that emerging researchers benefit from mentorship and integrated scientific networks. Core services must be operated or overseen by recognized experts and are designed to be shared across center members to maximize impact and efficiency. The Scientific Catalyst Program specifically supports activities that build research capacity, encourage cross-disciplinary partnerships, and align scientific efforts with the center’s focus on chronic diseases. Applications are expected to demonstrate how the proposed infrastructure will enhance existing strengths and expand the institute’s research trajectory. The funding opportunity was posted on July 2, 2026, and inquiries should be directed to the designated NIDDK contact for further details.
National Institutes Of Health

POSTED

3 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Bioinformatics and Genomics support services - Navy Medical Research CommandThe Naval Medical Research Command is seeking high-quality bioinformatics and genomics support services through a Request for Information targeting non-personal services to advance biological defense research at Fort Detrick, Maryland. The solicitation, numbered 20260000382 and issued by the Naval Supply Systems Command Fleet Logistics Center Norfolk, targets contractors capable of delivering next-generation sequencing, metagenomic analysis, pathogen characterization, and bacteriophage genome sequencing in support of epidemic response efforts. Contract performance is centered on federal facilities, requiring all personnel to be U.S. citizens with applicable security clearances—specifically Secret clearance for research and bioinformatics leadership roles and T3 or T1 background investigations for IT and other support positions. Access to federally controlled facilities and protected systems mandates compliance with stringent security protocols including annual cyber training, JPAS compliance, and submission of SF-85 forms, fingerprint cards, and signed releases. The contractor must designate a Security Representative within three days of award and maintain continuous compliance with all personnel vetting and access control requirements. The contract is structured as a Cost Plus Fixed Fee (CPFF) task order with a base period of one year from September 2026 through September 2027 and four one-year option periods plus a single six-month extension, allowing for a maximum performance period of 66 months. Funding will be awarded incrementally under supplemental clause SUPTXT 232.9400 (1-92), with annual cost estimates of $75,000 for travel and $750,000 for other direct costs, resulting in a potential total value of up to $4.5 million. All travel and ODCs require pre-approval via email from both the Contracting Officer’s Representative and Principal Investigator. Deliverables include high-throughput genomic data, phylogenetic analyses, and submissions to public databases such as GenBank, with monthly status reports and cost vouchers submitted through WAWF. Performance will be evaluated using a risk-based qualitative assessment framework with adjectival ratings—Excellent, Acceptable, Unacceptable—based on technical compliance, schedule and cost control, customer responsiveness, and overall satisfaction, with inspection conducted entirely by the Government via the Quality Assurance Surveillance Plan aligned with the Performance Work Statement. Offerors must submit a single searchable PDF not exceeding four pages, including proof of DCAA-approved accounting, DUNS and CAGE codes, small business status, technical synopsis, and two past performance references, all due
Navsup Flt Logistics Ctr Norfolk

POSTED

4 days ago

DEADLINE

in 3 days
View Details